Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 700 of 1329 entries
View as:

Botox for Gummy Smile

Phase: N/A Priority: Normal
NCT ID: NCT03284047 Org: User:
Start: 04/24/19 End: 04/24/19 Due: 04/24/20

Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01853644 Org: User:
Start: 06/06/13 End: 05/11/21 Due: 05/11/22

Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00073866 Org: User:
Start: 06/30/03 End: 12/31/04 Due: 12/31/05

Impact of Artificial Intelligence on Trainee Polyp Miss Rates

Phase: N/A Priority: Normal
NCT ID: NCT06676930 Org: User:
Start: 09/10/24 End: 09/30/26 Due: 09/30/27

Cholesterol and CYP3A4/5 Metabolism Across Pregnancy and Postpartum

Phase: N/A Priority: Normal
NCT ID: NCT05504889 Org: User:
Start: 06/17/22 End: 06/30/23 Due: 06/30/24

Improving Rates of Colorectal Cancer Screening Among Never Screened Patients

Phase: N/A Priority: Normal
NCT ID: NCT01742169 Org: User:
Start: 01/31/13 End: 06/30/14 Due: 06/30/15

Reletex for Nausea in GERD Patients

Phase: N/A Priority: Normal
NCT ID: NCT01582100 Org: User:
Start: 03/31/12 End: 11/30/13 Due: 11/30/14

Investigation of Efficacy of Improved Acetaminophen Labeling

Phase: N/A Priority: Normal
NCT ID: NCT01592448 Org: User:
Start: 10/31/12 End: 03/31/13 Due: 03/31/14

Ulcerative Colitis Relapse Prevention Trial, Hypnosis

Phase: N/A Priority: Normal
NCT ID: NCT00798642 Org: User:
Start: 07/31/07 End: 06/30/12 Due: 06/30/13

A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL

Phase: N/A Priority: Normal
NCT ID: NCT00858117 Org: User:
Start: 09/26/05 End: 01/24/13 Due: 01/24/14

Oxytocin and Pain Sensitivity and Threshold

Phase: N/A Priority: Normal
NCT ID: NCT01988649 Org: User:
Start: 04/30/15 End: 07/31/15 Due: 07/31/16

Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)

Phase: N/A Priority: Normal
NCT ID: NCT01408901 Org: User:
Start: 09/30/11 End: 08/15/17 Due: 08/15/18

A Pilot Study of Needle Size and Pain Perception With Botulinum Toxin A Injections

Phase: N/A Priority: Normal
NCT ID: NCT01981174 Org: User:
Start: 11/30/13 End: 01/31/14 Due: 01/31/15

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

Phase: N/A Priority: Normal
NCT ID: NCT06123026 Org: User:
Start: 12/18/23 End: 06/30/24 Due: 06/30/25

APOL1 Genetic Testing Program for Living Donors, Part 2

Phase: N/A Priority: Normal
NCT ID: NCT04999436 Org: User:
Start: 07/19/22 End: 01/17/25 Due: 01/17/26

Regimen Education and Messaging in Diabetes (REMinD)

Phase: N/A Priority: Normal
NCT ID: NCT03185741 Org: User:
Start: 01/05/18 End: 11/30/22 Due: 11/30/23

Affective and Cognitive Responses to Acute Bouts of Physical Activity and Mindfulness Training

Phase: N/A Priority: Normal
NCT ID: NCT04078464 Org: User:
Start: 08/26/19 End: 11/15/19 Due: 11/15/20

Efficacy of Gadoterate Meglumine in Diagnosis of Vascular Diseases Using MRA MRA

Phase: N/A Priority: Normal
NCT ID: NCT05199792 Org: User:
Start: 06/02/17 End: 01/01/20 Due: 01/01/21

A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging

Phase: N/A Priority: Normal
NCT ID: NCT02993198 Org: User:
Start: 04/30/15 End: 12/31/25 Due: 12/31/26

Spoken Discourse Biomarker of PD Cognitive Impairment

Phase: N/A Priority: Normal
NCT ID: NCT05909163 Org: User:
Start: 03/05/19 End: 02/15/23 Due: 02/15/24

Text Messaging for Human Immunodeficiency Virus (HIV) Testing in Sexual and Gender Minority (SGM) Teens

Phase: N/A Priority: Normal
NCT ID: NCT06096519 Org: User:
Start: 06/13/24 End: 06/30/26 Due: 06/30/27

Effects of Epigenetic Regulation in Chronic Pelvic Pain Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT05185180 Org: User:
Start: 10/11/21 End: 12/11/25 Due: 12/11/26

Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study

Phase: N/A Priority: Normal
NCT ID: NCT03667404 Org: User:
Start: 11/06/18 End: 03/31/26 Due: 03/31/27

Maximizing Outcomes for Preschoolers With Developmental Language Disorders

Phase: N/A Priority: Normal
NCT ID: NCT03782493 Org: User:
Start: 04/04/19 End: 02/22/25 Due: 02/22/26

Investigational MRI Clinical Software and Hardware

Phase: N/A Priority: Normal
NCT ID: NCT05215132 Org: User:
Start: 12/19/19 End: 01/31/26 Due: 01/31/27